Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 83

Results For "day"

2855 News Found

Sanofi India MD Rodolfo Hrosz to step down on April 30
People | April 11, 2025

Sanofi India MD Rodolfo Hrosz to step down on April 30

The board of directors accepted Hrosz’s resignation and expressed appreciation for his significant contributions during his tenure


NATCO Pharma updates on legal proceedings on Risdiplam launch in India
News | April 08, 2025

NATCO Pharma updates on legal proceedings on Risdiplam launch in India

NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court


Dr Reddy’s Laboratories gets Rs 2,395 crore show cause notice from IT authority
News | April 07, 2025

Dr Reddy’s Laboratories gets Rs 2,395 crore show cause notice from IT authority

Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws


Delhi becomes 35th state/UT to implement AB PM-JAY
Policy | April 07, 2025

Delhi becomes 35th state/UT to implement AB PM-JAY

Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme


Plex Research partners With Ginkgo Bioworks on AI powered drug discovery to identify novel disease mechanisms
News | April 07, 2025

Plex Research partners With Ginkgo Bioworks on AI powered drug discovery to identify novel disease mechanisms

Findings likely to generate hypotheses about potential new uses of drugs


Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis
News | April 07, 2025

Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis

Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers


AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer
Drug Approval | April 04, 2025

AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone


Enhertu approved in EU in post-ET breast cancer
Drug Approval | April 04, 2025

Enhertu approved in EU in post-ET breast cancer

Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease